Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
Go back to Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026| Diversified Corporate Resources, Inc. (NASDAQ: IRD) | Delayed: 3.51 -0.31 (8.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.82 | 52 Week High | $0.02 | |||
| Open | $3.79 | 52 Week Low | $0.02 | |||
| Day High | $3.83 | P/E | N/A | |||
| Day Low | $3.44 | EPS | $0.00 | |||
| Volume | 799,082 | |||||



